MX2021012035A - Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos. - Google Patents

Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos.

Info

Publication number
MX2021012035A
MX2021012035A MX2021012035A MX2021012035A MX2021012035A MX 2021012035 A MX2021012035 A MX 2021012035A MX 2021012035 A MX2021012035 A MX 2021012035A MX 2021012035 A MX2021012035 A MX 2021012035A MX 2021012035 A MX2021012035 A MX 2021012035A
Authority
MX
Mexico
Prior art keywords
causing agents
methods
disease
disease causing
phagocytosis
Prior art date
Application number
MX2021012035A
Other languages
English (en)
Inventor
Chanty Mariategue Chan
Nenad Tomasevic
Panagiotis Fotakis
Ruo Shi Shi
Adam Lewis Salles
Original Assignee
Dren Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dren Bio Inc filed Critical Dren Bio Inc
Publication of MX2021012035A publication Critical patent/MX2021012035A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción se refiere a un método para agotar o reducir los números de agentes que provocan enfermedades, incluidas células hospedadoras, o productos de células hospedadoras, microbios o sus productos en un sujeto humano tras la administración de una molécula que provoca fagocitosis dirigida y comprende un dominio de unión que se une un receptor fagocitótico específico, tal como Dectina-1, y un dominio de unión que se une a un agente específico que provoca enfermedad. En una modalidad específica, un método de la descripción agota o reduce en tejidos, sangre o médula ósea el número de agentes que provocan enfermedades mediante fagocitosis dirigida.
MX2021012035A 2019-04-05 2020-04-03 Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos. MX2021012035A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830139P 2019-04-05 2019-04-05
PCT/US2020/026721 WO2020206354A1 (en) 2019-04-05 2020-04-03 Methods of depleting disease causing agents via antibody targeted phagocytosis

Publications (1)

Publication Number Publication Date
MX2021012035A true MX2021012035A (es) 2022-03-11

Family

ID=72667025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012035A MX2021012035A (es) 2019-04-05 2020-04-03 Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos.

Country Status (12)

Country Link
US (1) US20220169737A1 (es)
EP (1) EP3947467A4 (es)
JP (1) JP2022527646A (es)
KR (1) KR20220031995A (es)
CN (1) CN114502585A (es)
AU (1) AU2020253621A1 (es)
BR (1) BR112021019950A2 (es)
CA (1) CA3136272A1 (es)
IL (1) IL286967A (es)
MX (1) MX2021012035A (es)
SG (1) SG11202110663UA (es)
WO (1) WO2020206354A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
KR20230005907A (ko) 2020-05-01 2023-01-10 볼트 바이오테라퓨틱스 인코퍼레이티드 항-dectin-2 항체
IL301956A (en) 2020-10-07 2023-06-01 Dren Bio Inc Antibodies against dectin-1 and methods of using them
WO2023196785A1 (en) * 2022-04-04 2023-10-12 Dren Bio, Inc. Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof
WO2023196786A1 (en) * 2022-04-04 2023-10-12 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2688591A4 (en) * 2011-03-22 2014-10-01 Baylor Res Inst TARGETING DENDRITIC CELLS FOR A TUBERCULOSIS VACCINE
US20200048371A1 (en) * 2017-03-31 2020-02-13 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
EP3824076A1 (en) * 2018-07-19 2021-05-26 Oncohost Ltd Il-31 improves efficacy of macrophage-based adoptive cell therapy for cancer

Also Published As

Publication number Publication date
BR112021019950A2 (pt) 2021-12-07
EP3947467A1 (en) 2022-02-09
WO2020206354A1 (en) 2020-10-08
CA3136272A1 (en) 2020-10-08
JP2022527646A (ja) 2022-06-02
CN114502585A (zh) 2022-05-13
AU2020253621A1 (en) 2021-11-11
US20220169737A1 (en) 2022-06-02
KR20220031995A (ko) 2022-03-15
SG11202110663UA (en) 2021-10-28
EP3947467A4 (en) 2023-01-04
IL286967A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
MX2021012035A (es) Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos.
EP4276114A3 (en) Cd20 binding single domain antibodies
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
UA94899C2 (ru) Фиксированное дозирование антител к her
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
Slade Shantz et al. Sutures versus staples for wound closure in orthopaedic surgery: a pilot randomized controlled trial
NZ737726A (en) Multispecific antigen-binding molecules and uses thereof
SI2780368T1 (en) INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
UA109633C2 (uk) Антитіло людини проти тканинного фактора
PH12015500297A1 (en) Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
EA201100239A1 (ru) Композиции, одновалетные в отношении связывания cd28, и способы их применения
CR20220521A (es) Anticuerpos
AU2006342119A8 (en) Soluble human M-CSF receptor and uses thereof
MX2021005085A (es) Formulacion de anticuerpo.
EA202092136A1 (ru) Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства
WO2014110353A8 (en) Notch ligand bound biocompatible substrates and their use in bone formation
WO2022031964A3 (en) Ifngr1 binding molecules and methods of use
ATE360442T1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
Bedard et al. Overall response rates to radiation therapy for patients with painful uncomplicated bone metastases undergoing initial treatment and retreatment
Talpur et al. A single-center experience with brentuximab vedotin in gamma delta T-cell lymphoma
MX2022005904A (es) Composiciones y metodos para la activacion de integrinas.
Kim et al. Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma
MX2010009640A (es) Uso de conjugados de interleucina-1 en el tratamiento de diabetes.